

Ronjon Chakraverty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8282865/publications.pdf>

Version: 2024-02-01

76
papers

5,796
citations

126907

33
h-index

91884

69
g-index

83
all docs

83
docs citations

83
times ranked

7063
citing authors

#	ARTICLE	IF	CITATIONS
1	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	512
2	Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLAâ€ peptide tetramers. <i>Journal of Experimental Medicine</i> , 2005, 202, 379-386.	8.5	466
3	Differential Regulation of Vitamin D Receptor and Its Ligand in Human Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 5382-5390.	0.8	407
4	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. <i>Blood</i> , 2002, 99, 4357-4363.	1.4	349
5	Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. <i>Blood</i> , 2002, 99, 1071-1078.	1.4	333
6	A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. <i>Blood</i> , 2014, 124, 1277-1287.	1.4	308
7	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
8	Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2011, 52, 49-57.	5.8	214
9	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 385, 228-238.	27.0	209
10	Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. <i>Blood</i> , 2004, 103, 2410-2416.	1.4	196
11	Vitamin D and barrier function: a novel role for extra-renal 1Î±-hydroxylase. <i>Molecular and Cellular Endocrinology</i> , 2004, 215, 31-38.	3.2	190
12	An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. <i>Journal of Experimental Medicine</i> , 2006, 203, 2021-2031.	8.5	170
13	Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 426-432.	1.6	152
14	The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. <i>Blood</i> , 2007, 110, 9-17.	1.4	150
15	T-Cellâ€ Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply Relapsed Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3695-3700.	1.6	134
16	Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cellâ€ Depleted Allogeneic Transplantation for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 971-978.	1.6	117
17	G-CSF mobilizes CD34 ⁺ regulatory monocytes that inhibit graft-versus-host disease. <i>Science Translational Medicine</i> , 2015, 7, 281ra42.	12.4	99
18	Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. <i>Blood</i> , 2006, 108, 2106-2113.	1.4	96

#	ARTICLE	IF	CITATIONS
19	High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 50-58.	2.0	94
20	Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. <i>Blood</i> , 2010, 116, 3080-3088.	1.4	92
21	Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. <i>Blood</i> , 2017, 130, 1327-1335.	1.4	83
22	Expression of 11 β -hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. <i>Blood</i> , 2005, 106, 2042-2049.	1.4	72
23	Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. <i>Blood</i> , 2018, 131, 917-931.	1.4	68
24	OX40- and CD27-Mediated Costimulation Synergizes with Anti-PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence. <i>Journal of Immunology</i> , 2015, 194, 125-133.	0.8	65
25	The Obese Liver Environment Mediates Conversion of NK Cells to a Less Cytotoxic ILC1-Like Phenotype. <i>Frontiers in Immunology</i> , 2019, 10, 2180.	4.8	61
26	Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2010, 90, 564-570.	1.0	57
27	HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. <i>Blood</i> , 2010, 115, 5147-5153.	1.4	56
28	Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. <i>Journal of Clinical Investigation</i> , 2010, 120, 3855-3868.	8.2	52
29	Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease ¹ . <i>Transplantation</i> , 2003, 75, 221-225.	1.0	49
30	Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skin. <i>Blood</i> , 2011, 117, 7063-7069.	1.4	41
31	Allogeneic Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1855-1863.	1.6	41
32	A wave of monocytes is recruited to replenish the long-term Langerhans cell network after immune injury. <i>Science Immunology</i> , 2019, 4, .	11.9	41
33	Redirection to the bone marrow improves T cell persistence and antitumor functions. <i>Journal of Clinical Investigation</i> , 2018, 128, 2010-2024.	8.2	39
34	Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs. <i>International Immunology</i> , 2005, 17, 1561-1572.	4.0	38
35	Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 640-648.	2.5	33
36	Conventional Dendritic Cells Are Required for the Activation of Helper-Dependent CD8 T Cell Responses to a Model Antigen After Cutaneous Vaccination with Lentiviral Vectors. <i>Journal of Immunology</i> , 2011, 186, 4565-4572.	0.8	32

#	ARTICLE	IF	CITATIONS
37	CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status. <i>Blood</i> , 2015, 125, 731-739.	1.4	32
38	Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 963.	4.8	30
39	The Host Environment Regulates the Function of CD8+ Graft-versus-Host-Reactive Effector Cells. <i>Journal of Immunology</i> , 2008, 181, 6820-6828.	0.8	29
40	Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity. <i>Journal of Clinical Investigation</i> , 2020, 130, 1896-1911.	8.2	27
41	Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1234-1241.	2.0	26
42	Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study. <i>Blood</i> , 2020, 136, 22-24.	1.4	24
43	Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2009, 88, 1312-1318.	1.0	23
44	Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease. <i>JCI Insight</i> , 2018, 3, .	5.0	23
45	Regulatory Mechanisms in Graft-versus-Host Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 2-6.	2.0	21
46	Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. <i>Blood</i> , 2011, 117, 6813-6824.	1.4	21
47	Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation. <i>Cancer Research</i> , 2015, 75, 2641-2652.	0.9	20
48	CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor. <i>Journal of Immunology</i> , 2015, 194, 1080-1089.	0.8	19
49	Dendritic cells in tissues: in situ stimulation of immunity and immunopathology. <i>Trends in Immunology</i> , 2012, 33, 8-13.	6.8	18
50	Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. <i>Haematologica</i> , 2020, 105, 2639-2646.	3.5	17
51	Role of Dendritic Cells in Graft-Versus-Host Disease. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 601-616.	1.8	14
52	Graft-versus-host disease: a disorder of tissue regeneration and repair. <i>Blood</i> , 2021, 138, 1657-1665.	1.4	14
53	Graft Versus Leukemia: Current Status and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2021, 39, 361-372.	1.6	11
54	Depletion of CD11c ⁺ cells in the CD11c.DTR model drives expansion of unique CD64 ⁺ Ly6C ⁺ monocytes that are poised to release TNF α . <i>European Journal of Immunology</i> , 2016, 46, 192-203.	2.9	10

#	ARTICLE	IF	CITATIONS
55	Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoid. <i>Blood</i> , 2013, 122, 3288-3297.	1.4	9
56	Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity. <i>Molecular Therapy</i> , 2017, 25, 504-511.	8.2	8
57	Host Environment Dictates the Outcome Following Transfer of Graft-Versus-Host Reactive Effector/Memory T Cells.. <i>Blood</i> , 2004, 104, 3046-3046.	1.4	7
58	Genome gains at chromosome 21q21/22 segment leads to co-amplification of Down Syndrome Critical Regions and known oncogenes in a case of donor cell-derived acute myeloid leukaemia following allogeneic sex mismatched umbilical cord blood transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 151, 285-288.	2.5	6
59	Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy. <i>Haematologica</i> , 2016, 101, 482-490.	3.5	6
60	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021, 56, 605-613.	2.4	6
61	An unexpected role for platelets in blocking Th17 differentiation. <i>Journal of Clinical Investigation</i> , 2014, 124, 480-482.	8.2	6
62	A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1367-1367.	1.4	5
63	CMV-IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. <i>Blood</i> , 2014, 124, 1109-1109.	1.4	5
64	T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 1177-1177.	1.4	5
65	Stem Cell Transplantation. , 0, , 419-435.		4
66	Families get mobilized to treat AML. <i>Blood</i> , 2011, 117, 746-748.	1.4	3
67	Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 682.e1-682.e12.	1.2	2
68	Stem Cell Transplantation. , 2015, , 651-675.		1
69	Proliferation, Expansion, Effector Differentiation and Survival of GVH-Reactive T Cells Following Delayed DLI to Mixed Chimeras.. <i>Blood</i> , 2004, 104, 594-594.	1.4	1
70	Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1225-1225.	1.4	1
71	Memory lapses in graft-versus-host disease. <i>European Journal of Immunology</i> , 2011, 41, 2530-2534.	2.9	0
72	Fondation Rene Touraine Pour La Dermatologie. <i>Experimental Dermatology</i> , 2012, 21, 802-814.	2.9	0

#	ARTICLE	IF	CITATIONS
73	Sequential Blockade and Engagement of Co-Stimulatory Pathways: A Potential Strategy for Amplifying Graft-Versus-Leukemia Responses without GVHD.. Blood, 2004, 104, 3075-3075.	1.4	0
74	De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.. Blood, 2006, 108, 2901-2901.	1.4	0
75	Peripheral Alloantigen Drives Early Dysfunction and Eventual Exhaustion of CTL Following Delayed Donor Leukocyte Infusions.. Blood, 2008, 112, 2346-2346.	1.4	0
76	Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 204-204.	1.4	0